U.S. Markets open in 4 hrs 56 mins
  • Gold

    1,777.60
    +7.10 (+0.40%)
     
  • EUR/USD

    1.1635
    -0.0003 (-0.0233%)
     
  • 10-Yr Bond

    1.6350
    0.0000 (0.00%)
     
  • Vix

    15.82
    -0.49 (-3.00%)
     
  • GBP/USD

    1.3783
    -0.0010 (-0.0744%)
     
  • USD/JPY

    114.3600
    0.0000 (0.0000%)
     
  • BTC-USD

    64,178.62
    +2,099.60 (+3.38%)
     
  • CMC Crypto 200

    1,486.08
    +22.73 (+1.55%)
     
  • FTSE 100

    7,205.76
    -11.77 (-0.16%)
     
  • Nikkei 225

    29,255.55
    +40.03 (+0.14%)
     

Amgen's Lumakras Combo Therapy Shows Improved Response Rate In Colorectal Cancer

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Amgen Inc (NASDAQ: AMGN) announced data from a Phase 1b/2 study evaluating the combination of Lumakras (sotorasib) with Vectibix (panitumumab) in patients with KRAS G12C-mutated advanced colorectal cancer.

  • Related Link: Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer.

  • The data showed that the combination therapy led to improved response rates.

  • The results were detailed at the European Society for Medical Oncology (ESMO21) congress.

  • Findings from the study showed that among 26 patients in the efficacy analysis set, the objective response rate (ORR) was 27%, while the disease control rate (DCR) was 81%.

  • In the expansion cohort of sotorasib-naïve patients with refractory CRC (n=18), 33% experienced a response (confirmed and unconfirmed).

  • "We are excited by these CodeBreaK 101 data, which show encouraging response rates that were much higher than the 9.7% response rate observed with Lumakras monotherapy," remarked David Reese, executive vice president of R&D.

  • Amgen says it has initiated a new Phase 3 trial with Lumakras plus Vectibix in the third-line setting of colorectal cancer.

  • Price Action: AMGN stock closed 0.97% higher at $218.13 on Wednesday.

  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.